Adding bevacizumab to standard chemotherapy improves overall survival for women with ovarian cancer
the ONA take:
Preliminary findings from the Gynecologic Oncology Group’s (GOG) GOG 213 study show an improvement in overall survival for women with ovarian cancer when bevacizumab is added to standard chemotherapy. The researchers report overall survival was a median 5 months longer for women who received chemotherapy plus bevacizumab than for women who received chemotherapy alone. These findings were presented at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer.
Median overall survival for women in the chemotherapy plus bevacizumab group was 42.2 months, compared with 37.3 months in the group who received chemotherapy alone. The additional drug improved progression-free survival by nearly 3.5 months (13.8 months for chemotherapy plus bevacizumab vs 10.4 months for chemotherapy alone). The ongoing study will assess quality of life in the women who also received bevacizumab and the role of secondary surgery before chemotherapy.
Preliminary findings from the Gynecologic Oncology Group’s (GOG) GOG 213 study show an improvement in overall survival for women with ovarian cancer when bevacizumab is added to standard chemotherapy.
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|